Cytokine & Growth Factor Reviews
Volume 21, Issue 2 , Pages 153-159, April 2010

Oncolytic viruses and histone deacetylase inhibitors—A multi-pronged strategy to target tumor cells

  • Thi Lien-Anh Nguyen

      Affiliations

    • Molecular Oncology Group, Lady Davis Institute - Jewish General Hospital, McGill University, Montreal, Quebec, Canada H3T 1E2
    • ,
  • Marnie Goodwin Wilson

      Affiliations

    • Dept. of Microbiology & Immunology, McGill University, Montreal, Quebec, Canada H3T 1E2
    • ,
  • John Hiscott

      Affiliations

    • Molecular Oncology Group, Lady Davis Institute - Jewish General Hospital, McGill University, Montreal, Quebec, Canada H3T 1E2
    • Dept. of Microbiology & Immunology, McGill University, Montreal, Quebec, Canada H3T 1E2
    • Department of Medicine, Jewish General Hospital, McGill University, Montreal, Quebec, Canada H3T 1E2
    • Corresponding Author InformationCorresponding author at: Lady Davis Institute for Medical Research, 3755 Cote Ste. Catherine, Montreal, Quebec, Canada H3T 1E2. Tel.: +1 514 340 8222x5265; fax: +1 514 340 7576.

published online 15 April 2010.

Abstract 

Oncolytic viruses (OVs) have shown promise as cancer therapeutics in pre-clinical and clinical testing; however, it is unlikely that OVs will constitute a stand-alone treatment. Histone deacetylase inhibitors (HDIs) represent a class of anticancer agents known to influence epigenetic modifications of chromatin, alter gene expression and manipulate a variety of signaling pathways, in some cases blunting the cellular antiviral response. Recent studies have shown that combining OV therapy with HDI treatment enhances viral replication and synergistically induces the killing of cancer cells in vitro and in vivo, an effect that has now been demonstrated in variety of virus/HDI combinations. This review discusses the results obtained with the different OV/HDI combinations, the rationale supporting these combinations and the advantages for oncolytic virus therapy.

Keywords: Oncolytic virus, Histone deacetylase inhibitors, Combination therapy, Innate immune response, Interferons

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1359-6101(10)00027-4

doi:10.1016/j.cytogfr.2010.03.002

Cytokine & Growth Factor Reviews
Volume 21, Issue 2 , Pages 153-159, April 2010

Article Tools

* Image Usage & Resolution